On the other hand, miR-494 is postulated as a therapeutic target in the progression of lung cancer, behaving as an oncogene due to its interaction with PTEN, and, although information is more scarce, miR-155 has been reported in blood as a potential diagnostic and prognostic biomarker in lung cancer [193,208]. This evidence concerns the gene PTEN and lung cancer.